Abstract:Background. Microarray technology enables a standardized, objective assessment of oncological diagnosis and prognosis. However, such studies are typically specific to certain cancer types, and the results have limited use due to inadequate validation in large patient cohorts. Discovery of genes commonly regulated in cancer may have an important implication in understanding the common molecular mechanism of cancer. Methods and Findings. We described an integrated gene-expression analysis of 2,186 samples from 39 studies to identify and validate a cancer type-independent gene signature that can identify cancer patients for a wide variety of human malignancies. The commonness of gene expression in 20 types of common cancer was assessed in 20 training datasets. The discriminative power of a signature defined by these common cancer genes was evaluated in the other 19 independent datasets including novel cancer types. QRT-PCR and tissue microarray were used to validate commonly regulated genes in multiple cancer types. We identified 187 genes dysregulated in nearly all cancerous tissue samples. The 187-gene signature can robustly predict cancer versus normal status for a wide variety of human malignancies with an overall accuracy of 92.6%. We further refined our signature to 28 genes confirmed by QRT-PCR. The refined signature still achieved 80% accuracy of classifying samples from mixed cancer types. This signature performs well in the prediction of novel cancer types that were not represented in training datasets. We also identified three biological pathways including glycolysis, cell cycle checkpoint II and plk3 pathways in which most genes are systematically up-regulated in many types of cancer. Conclusions. The identified signature has captured essential transcriptional features of neoplastic transformation and progression in general. These findings will help to elucidate the common molecular mechanism of cancer, and provide new insights into cancer diagnostics, prognostics and therapy.

Identification of Common Tumor Signatures Based on Gene Set Enrichment Analysis.

Common Human Cancer Genes Discovered by Integrated Gene-Expression Analysis

A Common Gene Expression Signature Analysis Method for Multiple Types of Cancer

Identification of Gene Expression Pattern Related to Breast Cancer Survival Using Integrated TCGA Datasets and Genomic Tools.

Multi-cancer molecular signatures and their interrelationships

Identification of Gene Signatures for COAD Using Feature Selection and Bayesian Network Approaches

Comprehensive Analysis of Differential Gene Expression to Identify Common Gene Signatures in Multiple Cancers

A tumor microenvironment gene set-Based prognostic signature for non-small-cell lung cancer

Identification of Tumor Mutation Burden, Microsatellite Instability, and Somatic Copy Number Alteration Derived Nine Gene Signatures to Predict Clinical Outcomes in STAD.

Molecular Signature of Cancer at Gene Level or Pathway Level? Case Studies of Colorectal Cancer and Prostate Cancer Microarray Data.

Inferring Pathway Crosstalk Networks Using Gene Set Co-Expression Signatures.

Computational Analysis of Expression of Human Embryonic Stem Cell-Associated Signatures in Tumors

Tumor-Specific Gene Expression Patterns With Gene Expression Proffles

Approaches to Uncovering Cancer Diagnostic and Prognostic Molecular Signatures.

Identiifcation and validation of a novel gene expression signature for diagnosing tumor tissue origin

Comprehensive Tissue-Specific Gene Set Enrichment Analysis and Transcription Factor Analysis of Breast Cancer by Integrating 14 Gene Expression Datasets

Identification of Cancer Trait Genes and Association Analysis under Pan-Cancer

Identification of Gene Signatures and Expression Patterns During Epithelial-to-Mesenchymal Transition From Single-Cell Expression Atlas

Tumor-specific Gene Expression Patterns with Gene Expression Profiles

Functional transcriptional signatures for tumor-type-agnostic phenotype prediction

Identification of a six-gene signature associated with tumor mutation burden for predicting prognosis in patients with invasive breast carcinoma